---
schema_version: "secwatch.filing_event.v1"
accession: "0000313616-26-000163"
form_type: "8-K"
ticker: "DHR"
cik: "0000313616"
company_name: "DANAHER CORP /DE/"
filed_at: "2026-07-20T21:55:01+00:00"
generated_at: "2026-07-21T10:05:56.300128+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Danaher Q2 2026 EPS $1.23 (up 60% YoY), raises full-year adjusted EPS guidance to $8.45-$8.60

## Summary
- Net earnings $870M ($1.23 diluted EPS) up 60% YoY; adjusted EPS $1.94 up 8.0%.
- Revenue $6.3B (+5.5% YoY); core revenue +3.0% (+4.5% ex-respiratory testing).
- Operating cash flow $1.5B, free cash flow $1.3B.
- Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55.
- Bioprocessing orders grew mid-teens; Life Sciences had strongest quarter in years.

## SEC filing metadata
- accession: 0000313616-26-000163
- form_type: 8-K
- ticker: DHR
- cik: 0000313616
- company_name: DANAHER CORP /DE/
- filed_at: 2026-07-20T21:55:01+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/0000313616-26-000163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313616/000031361626000163/dhr-20260721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313616-26-000163
- JSON: https://secwatch.observer/filing/0000313616-26-000163.json
- Plain text: https://secwatch.observer/filing/0000313616-26-000163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.